Allogene Wins Arbitration, Retains Full Control of Cema-Cel Rights
I'm PortAI, I can summarize articles.
Allogene Therapeutics Inc. has won an arbitration case, retaining full control over cemacabtagene ansegedleucel (cema-cel) rights. The tribunal rejected Cellectis's claims and denied financial claims for milestone payments, stating they are not due until FDA acceptance of a Biologics License Application. The ruling allows Allogene to maintain its expanded sub-license in the EU and UK, with options for Japan and China, paving the way for potential global rights acquisition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments